Provided by Tiger Trade Technology Pte. Ltd.

NeuroBo Pharmaceuticals, Inc.

2.36
0.0000
Volume:- -
Turnover:31.15K
Market Cap:20.33M
PE:-0.55
High:2.36
Open:2.36
Low:2.36
Close:2.36
52wk High:6.75
52wk Low:2.08
Shares:8.62M
Float Shares:2.20M
Volume Ratio:- -
T/O Rate:- -
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.2946
EPS(LYR):-2.4590
ROE:-160.76%
ROA:-74.35%
PB:1.57
PE(LYR):-0.96

Loading ...

Company Profile

Company Name:
NeuroBo Pharmaceuticals, Inc.
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
- -
Office Location:
- -
Zip Code:
- -
Phone:
- -
Fax:
- -
Introduction:
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy for both NASH and T2D; and DA-1726, a novel oxyntomodulin analogue functioning as a GLP1R/GCGR dual agonist for the treatment of NASH and obesity. The company also develops ANA001, a proprietary oral niclosamide formulation for the treatment of patients with moderate COVID-19; NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene for various indications, including COVID-19 in combination with ANA001. NeuroBo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.